IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $13.00 | Buy | Alliance Global Partners |
| 5/18/2026 | $20.00 | Buy | Maxim Group |
| 4/24/2026 | $15.00 | Buy | BTIG Research |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00
Maxim Group initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00
BTIG Research initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $15.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)
Fastest customizable press release news feed in the world
DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics. The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous system. That is
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies. Maxim Group and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company's current market position. BTIG Research also recently launched coverage with a advantageous rating and target, reflecting
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp
DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. At the center of this narrative sits a lesser-known but increasingly watched name: NeOnc Technologies (NASDAQ:NTHI), a company whose leadership is making a bold, highly vi
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments. While insider buying is never a guarantee of upside, it frequently reflects conviction rooted in operational visibility, upcoming catalysts, or perceived undervaluation. Here's a closer look at five companies where insider activity is turning heads, and potentially signaling deeper narratives unfolding beneath the surface. NeOnc Technolo
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones. Over the past year, Mr. Heshmatpour has invested nearly $1 million of personal capital into NeOnc shares. In r
Insider buying indicates management's conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout - expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study - within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. ("NTHI" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Chairman and CEO Amir Heshmatpour has purchased approximately $300,000 worth of NTHI stock in the last week, demonstrating managem
CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "Q4 2025 and early 2026 marked important inflection points for NeOnc. We completed NEO212's Phase 1 dose escalation and established a recommended Phase 2 dose of 610 mg, with early sig
Live finance-specific insights
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second
CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time. During the call, members of the NeOnc management team and independent members of the Company's Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc's proprietary bioconjugated
CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter & Recent Corporate Highlights Middle East – NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42's IROS, and completing ADGM incorpora
CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company's lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)–mutant high-grade glioma (WHO Grade III and IV). The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026. "Compl
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, members of the NTHI management team and independent members of the company's Scientific Advisory Board (SAB) will present data updates from the Company's ongoing Phase 1/2a NEO100-1 clinical trial and
Live Leadership Updates
CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said
CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Di
CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv
CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. "We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board," said Amir F. Heshmatpour, Executive Chairman and P
CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings. "We are incredibly ho
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (NASDAQ:BGL) ("Blue Gold" or the "Company"), a next-generation gold development and technology company, today announced the appointment of Sameer Salgar, Founding Partner and Chief Financial Officer of Quazar Investment, to its Advisory Board. Sameer brings over 20 years of investment, corporate finance, and strategic advisory experience. As co-founder of Quazar Investment, a UAE-based private investment firm, he has built a reputation for leading transformational cross-border transactions and connecting growth companies with global capital partners. His addition to the Advisory Board underscores Blue Gold's commitment to scal
CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Patent Transfer Agreement with McMaster University, features cutting-edge 3D bioprinting, artificial intelligence, and quantum modeling technologies designed to accelerate preclinical drug dis
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational
8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
SCHEDULE 13G - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Subject)
10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
10-K/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
S-3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)
8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)